World Library  
Flag as Inappropriate
Email this Article

Ecopipam

Article Id: WHEBN0023683974
Reproduction Date:

Title: Ecopipam  
Author: World Heritage Encyclopedia
Language: English
Subject: List of dopaminergic drugs, Dopamine receptor D1, Nafadotride, SKF-89,145, AS-8112
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Ecopipam

Ecopipam
Systematic (IUPAC) name
(–)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo[d]naptho-(2,1-b)azepine
Clinical data
Legal status
?
Identifiers
CAS number  YesY
ATC code None
PubChem
UNII  YesY
Chemical data
Formula C19H20ClNO 
Mol. mass 313.821 g/mol
 YesY   

Ecopipam (SCH-39166) is a synthetic benzazepine derivative drug that acts as a selective dopamine D1/D5 receptor antagonist, with little affinity for either dopamine D2-like or 5-HT2 receptors.[1]

Chemical synthesis

Ecopipam can be synthesized from a simple tetralin derivative:[2]

Clinical trials

Based on its profile in animal models, Ecopipam was first studied as a treatment for schizophrenia but showed no activity.[3][4] Side effects including sedation, restlessness, emesis and anxiety were generally rated mild. There were no reports of Parkinsonian-like extrapyramidal symptoms typically seen with D2 antagonists.

Human clinical studies also showed that Ecopipam was an effective antagonist of the acute euphoric effects of cocaine.[5] However, the effect did not persist following repeated administration.[6]

Researchers have postulated that dopamine via D1 receptors in the mesolimbic system is involved with rewarded behaviors and pleasure.[7] One such behavior is eating, and Ecopipam has been shown in a large clinical study to be an effective treatment for obesity.[8] However, reports of mild-to-moderate, reversible anxiety and depression made it unsuitable for commercialization as an anti-obesity drug, and its development was stopped.

Recent (2014) open label studies have shown Ecopipam to reduce gambling behaviors in subjects with pathological gambling[9] and to decrease the motor and vocal tics in adults with Tourette’s Syndrome.[10] Ecopipam is currently in clinical trials conducted by the biotechnology company Psyadon Pharmaceuticals for the treatment of Tourette’s Syndrome in children ages 7–17.[11]

References

  1. ^ Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A (December 1988). "Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity". The Journal of Pharmacology and Experimental Therapeutics 247 (3): 1093–102.  
  2. ^ Hou, D; Schumacher, D (2001). "The selection of a commercial route for the D1 antagonist Sch-39166.". Current opinion in drug discovery & development 4 (6): 792–9.  
  3. ^ Karlsson P, Smith L, Farde L, Härnryd C, Sedvall G, Wiesel FA (October 1995). "Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients". Psychopharmacology (Berl) 121 (3): 309–16.  
  4. ^ Den Boer JA, van Megen HJ, Fleischhacker WW, Louwerens JW, Slaap BR, Westenberg HG, Burrows GD, Srivastava ON (October 1995). "Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia". Psychopharmacology (Berl) 121 (3): 317–22.  
  5. ^ Haney M, Ward AS, Foltin RW, Fischman MW (June 2001). "Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans". Psychopharmacology (Berl) 155 (4): 330–7.  
  6. ^ Nann-Vernotica E, Donny EC, Bigelow GE, Walsh SL (June 2001). "Repeated administration of the D1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine". Psychopharmacology (Berl) 155 (4): 338–47.  
  7. ^ Baik JH (October 11, 2013). "Dopamine signaling in reward-related behaviors". Front Neural Circuits 7: 152.  
  8. ^ Astrup A, Greenway FL, Ling W, Pedicone L, Lachowicz J, Strader CD, Kwan R; Ecopipam Obesity Study Group (2007). "Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects". Obesity 15 (7): 1717–31.  
  9. ^ Grant JE, Odlaug BL, Black DW, Fong T, Davtian M, Chipkin R, Kim SW (August 2014). "A single-blind study of 'as-needed' ecopipam for gambling disorder". Ann Clin Psychiatry 26 (3): 179–86.  
  10. ^ Gilbert DL, Budman CL, Singer HS, Kurlan R, Chipkin RE (January–February 2014). "A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome". Clin Neuropharmacol 37 (1): 26–30.  
  11. ^ http://clinicaltrials.gov/ct2/show/study/NCT02102698
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.